Verastem, Inc. (0LOV.L)
USD 4.46
(-7.56%)
USD 4.46
(-7.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -37.27 Million USD | 22.12% |
| 2022 | -47.86 Million USD | 51.15% |
| 2021 | -97.99 Million USD | -116.6% |
| 2020 | -45.24 Million USD | -170.67% |
| 2019 | 64.01 Million USD | 780.03% |
| 2018 | -9.41 Million USD | 86.02% |
| 2017 | -67.34 Million USD | -108.19% |
| 2016 | -32.34 Million USD | 70.66% |
| 2015 | -110.25 Million USD | -225.24% |
| 2014 | -33.9 Million USD | -79.47% |
| 2013 | -18.88 Million USD | -87.09% |
| 2012 | -10.09 Million USD | 51.82% |
| 2011 | -20.95 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -41.5 Million USD | -38.97% |
| 2024 Q1 | -29.86 Million USD | 19.88% |
| 2023 Q3 | -52.95 Million USD | 62.34% |
| 2023 Q1 | -54.32 Million USD | -13.48% |
| 2023 Q2 | -140.59 Million USD | -158.82% |
| 2023 Q4 | -37.27 Million USD | 29.6% |
| 2023 FY | -37.27 Million USD | 22.12% |
| 2022 Q4 | -47.86 Million USD | 6.24% |
| 2022 Q3 | -51.05 Million USD | 17.74% |
| 2022 Q1 | -19.5 Million USD | 80.1% |
| 2022 FY | -47.86 Million USD | 51.15% |
| 2022 Q2 | -62.06 Million USD | -218.27% |
| 2021 Q1 | -12.48 Million USD | 72.41% |
| 2021 FY | -97.99 Million USD | -116.6% |
| 2021 Q3 | -20.99 Million USD | -1377.13% |
| 2021 Q4 | -97.99 Million USD | -366.85% |
| 2021 Q2 | -1.42 Million USD | 88.62% |
| 2020 Q4 | -45.24 Million USD | 58.99% |
| 2020 Q3 | -110.31 Million USD | -67.84% |
| 2020 Q1 | -76 Million USD | -218.72% |
| 2020 Q2 | -65.72 Million USD | 13.52% |
| 2020 FY | -45.24 Million USD | -170.67% |
| 2019 Q1 | 34.45 Million USD | 466.04% |
| 2019 Q2 | 24.74 Million USD | -28.19% |
| 2019 Q3 | 36.76 Million USD | 48.57% |
| 2019 Q4 | 64.01 Million USD | 74.14% |
| 2019 FY | 64.01 Million USD | 780.03% |
| 2018 Q4 | -9.41 Million USD | 91.09% |
| 2018 Q2 | -143.78 Million USD | -191.65% |
| 2018 Q1 | -49.3 Million USD | 26.8% |
| 2018 FY | -9.41 Million USD | 86.02% |
| 2018 Q3 | -105.66 Million USD | 26.51% |
| 2017 Q3 | -48.93 Million USD | -93.5% |
| 2017 FY | -67.34 Million USD | -108.19% |
| 2017 Q1 | -25.93 Million USD | 19.84% |
| 2017 Q4 | -67.34 Million USD | -37.63% |
| 2017 Q2 | -25.29 Million USD | 2.47% |
| 2016 Q2 | -39.56 Million USD | -161.2% |
| 2016 Q1 | -15.14 Million USD | 39.1% |
| 2016 Q3 | -37.27 Million USD | 5.79% |
| 2016 Q4 | -32.34 Million USD | 13.21% |
| 2016 FY | -32.34 Million USD | 70.66% |
| 2015 Q3 | -19.83 Million USD | 43.62% |
| 2015 FY | -110.25 Million USD | -225.24% |
| 2015 Q2 | -35.17 Million USD | -16.75% |
| 2015 Q4 | -24.87 Million USD | -25.41% |
| 2015 Q1 | -30.12 Million USD | 11.14% |
| 2014 Q1 | -13.24 Million USD | 29.89% |
| 2014 FY | -33.9 Million USD | -79.47% |
| 2014 Q4 | -33.9 Million USD | -64.91% |
| 2014 Q3 | -20.55 Million USD | 8.19% |
| 2014 Q2 | -22.39 Million USD | -69.07% |
| 2013 Q4 | -18.88 Million USD | 16.57% |
| 2013 FY | -18.88 Million USD | -87.09% |
| 2013 Q1 | -28.24 Million USD | -179.76% |
| 2013 Q2 | -13.88 Million USD | 50.86% |
| 2013 Q3 | -22.64 Million USD | -63.11% |
| 2012 Q1 | -25.47 Million USD | -21.55% |
| 2012 Q3 | -11.12 Million USD | 29.36% |
| 2012 Q4 | -10.09 Million USD | 9.26% |
| 2012 FY | -10.09 Million USD | 51.82% |
| 2012 Q2 | -15.75 Million USD | 38.16% |
| 2011 FY | -20.95 Million USD | 0.0% |
| 2011 Q4 | -20.95 Million USD | 66.11% |
| 2011 Q3 | -61.82 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 63.791% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 118.821% |
| Dynavax Technologies Corporation | 106.63 Million USD | 134.959% |
| Illumina, Inc. | 1.21 Billion USD | 103.071% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.29% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 121.025% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.139% |
| Biogen Inc. | 6.28 Billion USD | 100.593% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -19.416% |
| bluebird bio, Inc. | 108.57 Million USD | 134.335% |
| Imunon, Inc. | -4.69 Million USD | -693.272% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 101.777% |
| Myriad Genetics, Inc. | 88.1 Million USD | 142.313% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 103.85% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -11.188% |
| Nektar Therapeutics | 210.24 Million USD | 117.731% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -313.465% |
| Perrigo Company plc | 3.32 Billion USD | 101.122% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 216.914% |
| Editas Medicine, Inc. | -87.11 Million USD | 57.209% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.453% |
| Waters Corporation | 1.96 Billion USD | 101.902% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 634.983% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 67.268% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 125.695% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 618.687% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 109.842% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -425.042% |
| Evolus, Inc. | 63.7 Million USD | 158.514% |
| Adicet Bio, Inc. | -142 Million USD | 73.749% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -1.288% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -37.557% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 108.127% |
| FibroGen, Inc. | 56.76 Million USD | 165.668% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 103.256% |
| OPKO Health, Inc. | 230.68 Million USD | 116.16% |
| Homology Medicines, Inc. | 18.43 Million USD | 302.191% |
| Geron Corporation | 14.76 Million USD | 352.544% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 102.351% |
| Exelixis, Inc. | -73.05 Million USD | 48.969% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 31.292% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 75.317% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 66.537% |
| Zoetis Inc. | 4.76 Billion USD | 100.783% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 81.344% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -270.152% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.61% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -155.819% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 103.536% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 72.468% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 102.7% |
| Blueprint Medicines Corporation | 702.83 Million USD | 105.304% |
| Insmed Incorporated | 721.62 Million USD | 105.166% |
| TG Therapeutics, Inc. | 17.86 Million USD | 308.7% |
| Incyte Corporation | -3.17 Billion USD | 98.826% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 104.868% |